Compare Micron Technology, Inc. (MU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Viatris Inc — how do they compare? Micron Technology, Inc. trades at $919.86 (market cap $980.90B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Micron Technology, Inc. is far larger — about 52.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| MU | VTRS | |
|---|---|---|
Market Cap | $980.90B | $18.69B |
Sector | Technology | Health |
52-Week High | $1.21K | $17.86 |
52-Week Low | $115.79 | $9.49 |
Enterprise Value | $961.25B | $30.80B |
Dividend Yield | 0.06% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $861.00, down 1.89% amid recent volatility despite strong fundamental performance. The stock shows neutral technical signals with key support at $845 and resistance at $886. Fundamentally, MU demonstrates exceptional profitability with 72.57% gross margins and 55.91% net income margins, supported by three consecutive quarterly earnings beats. Revenue growth accelerated to $37.38 billion in 2025 from $25.1 billion in 2024, with projected 2026 revenue of $90.3 billion indicating robust AI-driven demand.
The outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 79% upside. However, cyclical memory market risks and competitive threats from new entrants like SpaceX's Terrafab facility pose challenges. The stock's current valuation at 19.63 P/E appears reasonable given projected earnings growth, making MU attractive for investors comfortable with semiconductor sector volatility.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
